On November 20, 2018 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at upcoming investor conferences, will hold a key opinion leader (KOL) event for the investment community, and will present data at the upcoming 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Aptose Biosciences, NOV 20, 2018, View Source [SID1234531491]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Jaffray 19th Annual Health Care Conference
Time: 4:00 pm ET
Date: Tuesday, November 27, 2018
Live Webcast: Piper Jaffray Conference Aptose Webcast Link
BMO Capital Markets Prescriptions for Success Healthcare Conference
Time: 11:40 am ET
Date: Wednesday, December 12, 2018
Live Webcast: BMO Capital Markets Aptose Webcast Link
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Time: 9:00 – 10:30 am ET
Date: Wednesday, December 12, 2018
Location: Lotte New York Palace Hotel, New York, NY
Live Webcast: Aptose KOL Presentation Webcast Link
The KOL event hosted by Aptose will feature Brian Druker, M.D, Director of Oregon Health & Science University’s Knight Cancer Institute. Dr. Druker is well known for his pioneering role in developing Gleevec for patients with chronic myeloid leukemia (CML) and for his efforts to accelerate the development of novel therapies for the treatment of acute myeloid leukemia (AML). At the KOL event, Dr. Druker will discuss the evolution of kinase inhibitors as anticancer drugs, review the current treatment landscape in AML and B-cell cancers, examine the unmet medical needs for these patient populations, and highlight his experience with Aptose’s CG-806 to potentially address these treatment challenges. Following Dr. Druker, the Aptose Biosciences management team will provide an update on CG-806, which is expected to enter clinical studies in early 2019.

The breakfast event is by invitation only (contact Morgen Alden, [email protected]) and will also be accessible by webcast.

American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting
Time: 6:00 – 8:00 pm PT
Date: December 2, 2018
Location: San Diego Convention Center, San Diego, CA
Aptose previously announced that preclinical data for its pan-FLT3/pan-BTK inhibitor CG-806 will be presented in two separate posters at the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition on Sunday, December 2, 2018 from 6:00-8:00 pm PT in San Diego, CA (link to announcement).

On November 20, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference (Press release, Syros Pharmaceuticals, NOV 20, 2018, View Source [SID1234531509]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

30th Annual Piper Jaffray Healthcare Conference
Date: Tuesday, November 27
Presentation Time: 4:30 p.m. ET
Location: Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the fireside chat

On November 20, 2018 Clovis Oncology, Inc. (NASDAQ:CLVS) reported that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations (Press release, Clovis Oncology, NOV 20, 2018, View Source [SID1234531510]). The patent claims cover methods of treating cancer with commercial Rubraca product, including all commercial dosage strengths (200, 250 and 300mg). The high dosage strength rucaparib formulation patent expires in 2035, and will join multiple patents directed to rucaparib, rucaparib camsylate, and methods of treatment as the 11th Orange Book-listed patent for rucaparib.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of treatment patent," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Each additional patent provides further protection for Rubraca, and this is relevant not only to our current indications in ovarian cancer, but also to multiple potential additional indications based on our ongoing and substantial clinical development programs."

About Rubraca (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. and Europe.

On November 19, 2018 City of Hope reported that it will present data on new findings on immunotherapies, including CAR T cell therapy, bone marrow transplants and other treatments for blood cancers, at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting Dec. 1-4 in San Diego (Press release, City of Hope, NOV 19, 2018, View Source [SID1234531447]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

City of Hope is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. The institution was a pioneer in bone marrow and stem cell transplants — and the transplantation program is now one of the largest, most successful programs of its kind in the U.S. Its CAR T therapy program was the first to treat patients with CAR T cells targeting the IL13Rα2 antigen in glioblastomas, and the first to offer CAR T trials targeting CD123 in acute myeloid leukemia.

City of Hope doctors will make special presentations at the ASH (Free ASH Whitepaper) conference. Joseph Alvarnas, vice president for government affairs and associate clinical professor of hematology and hematopoietic cell transplantation, will chair an ASH (Free ASH Whitepaper) Practice Partnership Lunch titled "How to Incorporate Palliative Care Into Practice: Addressing Barriers and Solutions," which addresses how patients with hematologic malignancies often have difficulty accessing high-quality symptom management and palliative care because of preconceived perceptions as well as limited reimbursement, and discusses solutions. The lunch takes place Sunday, Dec. 2, 2018, 11:15 a.m.-12:30 p.m., in the Marina Ballroom G (Marriott Marquis San Diego Marina).

City of Hope researchers will also make presentations on the following data:

610: CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL
Type: Oral
Session: 731. Clinical Autologous Transplantation
Session Date and Time: Monday, Dec. 3, 2018: 7:45 a.m.
Location: Grand Hall B (Manchester Grand Hyatt San Diego)
Presenter: Leslie Popplewell, M.D., associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation

965: The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma
Type: Oral
Session: 703. Adoptive Immunotherapy: Preclinical Studies to Improve Safety and Efficacy of CAR-T Cells
Session Date and Time: Monday, Dec. 3, 2018: 5:30 p.m.
Location: San Diego Ballroom B (Marriott Marquis San Diego Marina)
Presenter: Xiuli Wang, Ph.D., research professor, Department of Hematology & Hematopoietic Cell Transplantation

399 Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Type: Oral
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Session Date and Time: Sunday, Dec. 2, 2018: 12:30 p.m.
Location: Pacific Ballroom 20 (Marriott Marquis San Diego Marina)
Presenter: Elizabeth Lihua Budde, M.D., Ph.D., assistant professor, Department of Hematology & Hematopoietic Cell Transplantation

300 Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Type: Oral
Session: 642. CLL: Therapy, excluding Transplantation
Session Date and Time: Sunday, Dec. 2, 2018: 8:45 a.m.
Location: Pacific Ballroom 20 (Marriott Marquis San Diego Marina)
Presenter: Tanya Siddiqi, assistant clinical professor, Department of Hematology & Hematopoietic Cell Transplantation

620: Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation
Type: Oral
Session: 904. Outcomes Research—Malignant Conditions: Outcomes in Lymphoid Malignancies and Stem Cell Transplant
Session Date and Time: Monday, Dec. 3, 2018: 7:15 a.m.
Location: Room 24B (San Diego Convention Center)
Presenter: Alex Iukuridze, clinical research assistant, Department of Population Sciences

611: Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"
Type: Oral
Session: 731. Clinical Autologous Transplantation
Session Date and Time: Monday, Dec. 3, 2018: 8 a.m.
Location: Grand Hall B (Manchester Grand Hyatt San Diego)
Presenter: Jasmine M. Zain, M.D., associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation, and director, T cell Lymphoma Program

4016 Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile
Type: Poster
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
Session Date and Time: Monday, Dec. 3, 2018, 6-8 p.m.
Location: Hall GH (San Diego Convention Center)
Presenter: Samer K. Khaled, M.D. assistant clinical professor, Department of Hematology & Hematopoietic Cell Transplantation

2181: Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
Type: Poster
Session: 732. Clinical Allogeneic Transplantation
Session Date and Time: Saturday, Dec. 1, 2018, 6:15-8:15 p.m.
Location: Hall GH (San Diego Convention Center)
Presenter: Rohan Gupta, clinical resident/fellow, Department of Medical Oncology & Therapeutics Research

1411: Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors
Type: Poster
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
Session Date and Time: Saturday, Dec. 1, 2018, 6:15-8:15 p.m.
Location: Hall GH (San Diego Convention Center)
Presenter: Hong Qin, Ph.D., associate research professor, Department of Hematology & Hematopoietic Cell Transplantation

3967: Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)
Type: Poster
Session: 612. Acute Lymphoblastic Leukemia
Session Date and Time: Monday, Dec. 3, 2018, 6-8 p.m.
Location: Hall GH (San Diego Convention Center)
Presenter: Anthony Stein, M.D., co-director, Gehr Family Center for Leukemia Research, clinical professor, Department of Hematology & Hematopoietic Cell Transplantation

On November 19, 2018 Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse Biosciences" or the "Company"), a novel medical therapy company bringing to market its proprietary CellFX Nano-Pulse Stimulation (NPS) platform, reported that it has commenced its previously announced rights offering of $45,000,000 of its common stock (Press release, Pulse Biosciences, NOV 19, 2018, View Source [SID1234531448]). The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on Thursday December 6, 2018 (the "Expiration Date").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the rights offering, Pulse Biosciences is distributing, at no charge to the holders of its common stock, non-transferable subscription rights to purchase up to $45,000,000 of shares of its common stock at a subscription price per share equal to the lesser of (i) $13.33 per share (the "Initial Price") or (ii) the volume weighted average price (the "Alternate Price") of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

Stockholders wishing to exercise subscription rights must timely pay $13.33 per share, the Initial Price, for the number of shares of common stock they wish to acquire. If the Alternate Price is lower than the Initial Price on the Expiration Date, any excess subscription amounts paid by a subscribing holder will be applied towards the purchase of additional shares in the rights offering. Stockholders who fully exercise their basic subscription rights will be entitled to subscribe for additional shares that are not purchased by other stockholders, on a pro rata basis and subject to availability and ownership limitations.

A registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on November 6, 2018. A prospectus relating to the offering was filed with the SEC on November 19, 2018 and is available on the SEC’s website.

Stockholders may exercise their subscription rights by delivering documentation of their subscription and payment in the manner specified in the prospectus relating to the rights offering. Beneficial stockholders (i.e. stockholders whose shares are in a brokerage account), should exercise their subscription rights as indicated in the instructions provided by their broker-dealer. Procedures and dates set-forth by broker-dealers may differ from those in offering documents. Investors wishing to participate in the Company’s offering are encouraged to contact their broker-dealer for further information.

Questions about the rights offering and requests for copies of the prospectus relating to the rights offering may be directed to Broadridge Corporate Issuer Solutions, Inc., the Company’s information and subscription agent for the rights offering, after the Record Date by calling (888) 789-8409 (toll-free) or by emailing [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer will be made only by means of the prospectus forming a part of the effective registration statement.